



19 March 2018

ASX Limited

SomnoMed Limited – Results of Retail Entitlement Offer

SomnoMed Limited is today pleased to announce the successful completion of the Retail Entitlement Offer. The retail component of the Entitlement Offer allowed eligible retail shareholders in SomnoMed to acquire one (1) New Share for every seventeen (17) existing shares at a price of \$3.00 per New Share.

Approximately 1.49 million New Shares will be issued under the Retail Entitlement Offer at an issue price of \$3.00 per New Share (Offer Price), raising approximately \$4.5 million. Approximately 62% of available retail entitlements were taken-up under the Retail Entitlement Offer. Approximately 20% of the Institutional Entitlement Offer and 38% of the Retail Entitlement Offer were renounced, comprising the entitlements not taken up by eligible shareholders and ineligible shareholders. The shortfall component under the Institutional Entitlement Offer has already been allocated and the shortfall from the Retail Entitlement Offer will be placed by the Board to TDM Asset Management Pty Ltd and other existing shareholders who participated in the Institutional Offer and had indicated their interest to acquire additional New Shares, in the event of there being any shortfall shares.

The issue of New Shares under the Retail Entitlement Offer is scheduled to occur on Thursday 22 March 2018 and these shares are expected to start trading on the Australian Securities Exchange on Friday 23 March 2018.

Following the completion of the Entitlement Offer, SomnoMed will have raised a total of approximately \$10.4 million from both the Institutional and Retail Entitlement Offers. Funds raised will provide working capital to enable SomnoMed to continue the rollout of its “Direct to Patient” Obstructive Sleep Apnea (“OSA”) model through its Renew Sleep Solutions (“RSS”) centres across North America.

The results of the Retail and Institutional Entitlement Offers highlight the recognition from shareholders of the long-term value in SomnoMed and a support for the initiatives of the Company.

Terry Flitcroft
Company Secretary
SomnoMed Limited

About SomnoMed

SomnoMed is a public company providing diagnostic and treatment solutions for Sleep-related Breathing Disorders including obstructive sleep apnea, snoring and bruxism. SomnoMed was commercialized on the basis of extensive clinical research. Supporting independent clinical research, continuous innovation and instituting medical manufacturing standards has resulted in SomnoDent® becoming the state-of-the-art and clinically proven medical oral appliance therapy for obstructive sleep apnea. SomnoDent® is the most comfortable and effective design and treatment solution for over 400,000 patients in 28 countries. For additional information, visit SomnoMed at <http://www.somnomed.com.au>